Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E7QB
|
|||
| Drug Name |
Mirikizumab
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Approved | [1] | |
| Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 3 | [2] | ||
| Company |
Eli Lilly Indianapolis, IN
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-12 alpha (IL12A) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Toll-like receptor signaling pathway | ||||
| RIG-I-like receptor signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Type I diabetes mellitus | ||||
| Pertussis | ||||
| Legionellosis | ||||
| Leishmaniasis | ||||
| Chagas disease (American trypanosomiasis) | ||||
| African trypanosomiasis | ||||
| Malaria | ||||
| Toxoplasmosis | ||||
| Amoebiasis | ||||
| Tuberculosis | ||||
| Measles | ||||
| Influenza A | ||||
| Herpes simplex infection | ||||
| Inflammatory bowel disease (IBD) | ||||
| Allograft rejection | ||||
| Pathway Interaction Database | IL27-mediated signaling events | |||
| IL12-mediated signaling events | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Allograft Rejection | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761279 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.